Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
Kanishka Manna, Prashanthi Dharanipragada, Duah Alkam, Nathan L. Avaritt, Charity L. Washam, Michael Scott Robeson, Tung-Chin Chiang, Ricky D. Edmondson, Samuel Mackintosh, Zhentao Yang, Yan Wang, Shirley Lomeli, Gatien Moriceau, Stephanie D. Byrum, Roger S. Lo, Alan J. Tackett
The paper presents a proteogenomic approach to identify resistance-specific alterations in melanoma PDX models treated with MAPK inhibitors using custom curated databases.
bioRxiv · Feb 15, 2022 · PreprintBioinformatics